{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92.6","upperLimit":"95.4","value":"94.2"},{"groupId":"OG001","lowerLimit":"90.2","upperLimit":"93.2","value":"91.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1420"},{"groupId":"OG001","value":"1420"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Patients who completed prior adjuvant trastuzumab received six 40 mg neratinib tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. Therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred.","id":"OG000","title":"Neratinib"},{"description":"Patients who completed prior adjuvant trastuzumab received six 40 mg placebo tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. Therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Intent to treat (ITT) population included all participants who were randomized regardless of whether they received any study treatment.","reportingStatus":"POSTED","timeFrame":"From randomization until time of event up to 2 years","title":"Kaplan-Meier Estimates of Invasive Disease-free Survival (iDFS) at Year 2 by Treatment Arms","type":"PRIMARY","unitOfMeasure":"percentage of participants"}